Five Drug Classes Show Promise for Extending Human Healthspan and Reversing Aging
Comprehensive review identifies senolytics, NAD+ precursors, mTOR inhibitors and other compounds targeting aging hallmarks.
Summary
This comprehensive review examines emerging pharmacological strategies for human anti-aging therapy, focusing on five key drug classes that target the nine hallmarks of aging. The authors analyze senolytics (like dasatinib and quercetin), senomorphics, NAD+ precursors, mTOR inhibitors, and metabolic modifiers including metformin. Early clinical trials show promise, with dasatinib plus quercetin reducing senescent cell burden in diabetic kidney disease patients and improving physical function. However, challenges remain including biomarker identification, safety concerns, and regulatory hurdles for translating promising preclinical results into clinical practice.
Detailed Summary
As global populations age rapidly, with 2 billion people expected to be over 60 by 2050, researchers are urgently developing pharmacological interventions to extend healthspan rather than just lifespan. This review examines five promising drug classes targeting the nine established hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.
The most advanced category is senolytics, drugs that selectively eliminate senescent cells responsible for chronic inflammation and tissue dysfunction. Dasatinib (a tyrosine kinase inhibitor) combined with quercetin (a dietary flavonoid) has shown clinical promise. In a pilot study of diabetic kidney disease patients, three days of treatment reduced senescent cell burden in adipose tissue and skin while improving physical function after three months. Fisetin, another senolytic compound, demonstrated superior cognitive protection in Alzheimer's disease models compared to dasatinib-quercetin combinations.
Other promising approaches include NAD+ precursors like nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), which restore mitochondrial metabolism and activate beneficial sirtuin signaling pathways. mTOR inhibitors such as rapamycin promote cellular cleanup through autophagy, while metabolic modifiers like metformin mimic caloric restriction benefits by activating AMPK pathways and improving insulin sensitivity.
Despite encouraging preclinical results across multiple species, significant challenges remain for clinical translation. These include identifying reliable aging biomarkers, ensuring long-term safety profiles, addressing regulatory frameworks not designed for aging interventions, and overcoming the historical exclusion of older adults from clinical trials due to comorbidities and polypharmacy concerns.
The interconnected nature of aging hallmarks suggests combination therapies may prove more effective than single interventions. As the field of geroscience matures, these pharmacological strategies represent a paradigm shift from treating individual age-related diseases toward targeting the fundamental biology of aging itself.
Key Findings
- Dasatinib plus quercetin reduced senescent cells and improved physical function in diabetic kidney disease patients
- Five drug classes target aging hallmarks: senolytics, senomorphics, NAD+ precursors, mTOR inhibitors, metabolic modifiers
- Fisetin outperformed dasatinib-quercetin in preserving cognitive function in Alzheimer's disease models
- Metformin and rapamycin extend lifespan in multiple animal models through different mechanisms
- Clinical trials are underway for aging interventions in frailty, osteoarthritis, and neurodegenerative diseases
Methodology
This is a narrative review analyzing preclinical and clinical evidence for anti-aging pharmacological interventions. The authors systematically examined drug classes targeting the nine established hallmarks of aging, reviewing mechanisms of action, preclinical efficacy data, and clinical translation potential.
Study Limitations
Most evidence comes from animal studies with limited human data. Challenges include lack of standardized aging biomarkers, unknown long-term safety profiles, and regulatory barriers. Many studies exclude older adults, limiting generalizability to target populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.